Advertisement
MISSISSAUGA, Ontario, April 22 /PRNewswire-FirstCall/ -- CardioGenics Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, will be spotlighted in three publications during the month of April: Today's Medical Developments, Medical Design Technology and The Wall Street Transcript.
In the April 2010 print and online editions of Today's Medical Developments, senior editor Elizabeth Engler Modic contributes an article titled "Going from Hours Down to Minutes Saves Lives." In the article, Modic describes the QL Care analyzer, a sensitive and accurate point-of-care (POC) analyzer, which was conceived and developed by a team led by CardioGenics founder and CEO Yahia Gawad, Ph.D. Gawad comments on the market need for a new POC analyzer that can reduce the time required to diagnose a cardiac event and other conditions, outlines the prototyping and testing phases, describes its advantages over existing products, and summarizes future steps leading up to its commercial release.
In the April 2010 print and online editions of Medical Design Technology, Dr. Gawad contributes an article titled "The QL Care Analyzer: A Leap Forward in POC Diagnostics." In the article, Gawad delves into the physical characteristics and technical operation of the QL Care analyzer. For example, he describes the device's use of patent-protected disposable test cartridges and its use of chemiluminescence to derive test results. The analyzer's memory processor, touch LCD screen, and internal printer are among the additional features he describes.
In a Q&A posted on The Wall Street Transcript website on April 5, 2010, Dr. Gawad provides a brief history of CardioGenics, describes why he chose to enter the In Vitro Diagnostics market, and provides additional details on the status of the QL Care analyzer. He highlights some of the challenges of securing the medical community's acceptance of new technology and of doing business during a time when US healthcare options are being dramatically overhauled.
Dr. Gawad remarked: "As CardioGenics continues to grow and to prepare its products for market, we welcome media attention that focuses on what we have to offer the healthcare community. We believe our QL Care analyzer and other products offer the possibility of saving many lives, and such exposure allows potential customers to become aware of our technology and how it could serve their patients."
To read the Today's Medical Developments article, please visit: http://www.onlinetmd.com/tmd-0410-test-results-improves-diagnosis.aspx
To read the Medical Design Technology article, please visit:
http://e-ditionsbyfry.com/Olive/ODE/MDT/ and click on p. 20 in the Table of Contents
To read an excerpt of The Wall Street Transcript Q&A, please visit:
www.twst.com
About CardioGenics Holdings Inc.
Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada.
Safe Harbor Statement
Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.
SOURCE CardioGenics Holdings Inc.
Advertisement
In the April 2010 print and online editions of Today's Medical Developments, senior editor Elizabeth Engler Modic contributes an article titled "Going from Hours Down to Minutes Saves Lives." In the article, Modic describes the QL Care analyzer, a sensitive and accurate point-of-care (POC) analyzer, which was conceived and developed by a team led by CardioGenics founder and CEO Yahia Gawad, Ph.D. Gawad comments on the market need for a new POC analyzer that can reduce the time required to diagnose a cardiac event and other conditions, outlines the prototyping and testing phases, describes its advantages over existing products, and summarizes future steps leading up to its commercial release.
In the April 2010 print and online editions of Medical Design Technology, Dr. Gawad contributes an article titled "The QL Care Analyzer: A Leap Forward in POC Diagnostics." In the article, Gawad delves into the physical characteristics and technical operation of the QL Care analyzer. For example, he describes the device's use of patent-protected disposable test cartridges and its use of chemiluminescence to derive test results. The analyzer's memory processor, touch LCD screen, and internal printer are among the additional features he describes.
In a Q&A posted on The Wall Street Transcript website on April 5, 2010, Dr. Gawad provides a brief history of CardioGenics, describes why he chose to enter the In Vitro Diagnostics market, and provides additional details on the status of the QL Care analyzer. He highlights some of the challenges of securing the medical community's acceptance of new technology and of doing business during a time when US healthcare options are being dramatically overhauled.
Dr. Gawad remarked: "As CardioGenics continues to grow and to prepare its products for market, we welcome media attention that focuses on what we have to offer the healthcare community. We believe our QL Care analyzer and other products offer the possibility of saving many lives, and such exposure allows potential customers to become aware of our technology and how it could serve their patients."
To read the Today's Medical Developments article, please visit: http://www.onlinetmd.com/tmd-0410-test-results-improves-diagnosis.aspx
To read the Medical Design Technology article, please visit:
http://e-ditionsbyfry.com/Olive/ODE/MDT/ and click on p. 20 in the Table of Contents
To read an excerpt of The Wall Street Transcript Q&A, please visit:
www.twst.com
About CardioGenics Holdings Inc.
Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada.
Safe Harbor Statement
Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.
SOURCE CardioGenics Holdings Inc.
